News
Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...
Antimicrobial drug developer HOOKIPA Pharma (NASDAQ:HOOK) announced Thursday that Gilead Sciences (NASDAQ:GILD) has agreed to ...
Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration ...
It would also have two Hookipa programmes partnered with Gilead Sciences, namely HB-500, an alternating, 2-vector arenaviral therapeutic vaccine that is being evaluated as part of a potential ...
Gilead is solely responsible for further development and commercialization of HB-400, referenced as GS-2829 and GS-6779. HOOKIPA earned a $5 million non-dilutive payment under its collaboration ...
The review process will not impact HOOKIPA’s operations or clinical ... including those in collaboration with Gilead, with the first person recently dosed in the Phase 1b clinical trial of ...
Gilead Sciences Inc.’s experimental twice-yearly shot prevented 100% of HIV cases in women and adolescent girls in Africa, the first successful big trial of what’s hoped to become a powerful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results